Beijing Hotgen Biotech Co., Ltd.

Beijing Hotgen Biotech Co., Ltd (Hotgen) is a biotechnology enterprise focusing on biomedicine and diagnostics, founded in Beijing, 2005 and listed on Shanghai Stock Exchange with a stock code of 688068 in 2019. Hotgen continuously explores independent innovative diagnostic technology platforms, actively develops cancer early screening technology, and has established multi-omics diagnostic technology platforms based on protein markers, exosomes, and DNA methylation. Hotgen’s in-house innovative technology incubation platform - Research Institution of Future Technology focuses on exploring the industrialization of frontier biotechnologies, and is now endeavoring into leading-edge biopharmaceutical fields such as antibody drugs, probiotic drugs, and nucleic acid drugs. Adhering to the mission of "develop biotechnology and benefit human health", we are committed to an industrial layout from diagnosis, treatment to health management.